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Dear Sir, 
We thank Professor Sinclair and colleagues for their helpful position statement addressing the 
important clinical problem of managing type 1 diabetes in older adults (1).  We believe that further 
considerations about the difficult area of making a diagnosis of type 1 diabetes in older adults would 
benefit future versions of these guidelines. 
The present guidelines do not emphasise how difficult this diagnosis is to make because in the older 
adult, where type 2 diabetes represents over 98% of all diabetes (2). The rarity of type 1 diabetes in 
this age group means that it is very hard to separate type 1 diabetes from an unusual presentation of 
type 2 diabetes. Errors are therefore common with post honeymoon C-peptide studies showing that 
50% of those treated with insulin from diagnosis do not have type 1 diabetes (3) and 40% of those 
with definite type 1 diabetes are initially treated with tablets (4). This means the reassessment of 
diagnosis in older adults treated with insulin is crucial. 
A Body Mass Index (BMI) ≤24kg/m2 is proposed as a reason for considering type 1 diabetes, which is 
reasonable but it is important to emphasise that most people with a normal BMI diagnosed over 50 
years will have type 2 diabetes and not type 1 diabetes.   With increasing age of diagnosis type 2 
diabetes develops at substantially lower BMI (5). In  UK general practice records, a BMI under 25 
kg/m2 is found in 7.2% of people presenting with type 2 diabetes after age 35 years, and 13.0% 
presenting after age 70 (personal communication Dennis JM – analysis Clinical Practice Research 
Datalink, n=70,150).  
Similarly, it is important to emphasise that the vast majority of older adults with diabetes and the 
clinical features of atypical presentation (rapid onset or ketosis at diagnosis), or a family history of 
autoimmune diabetes will not have type 1 diabetes. These factors were not supported as having 
evidence of diagnostic utility for differentiating between type 1 and type 2 diabetes on systematic 
review (6). Even if ketosis or family history of autoimmunity are more common in type 1 diabetes 
this does not mean they are substantially predictive of type 1 diabetes in this age group. Based on 
data from 1048 participants with adult onset diabetes (7), in a population with diabetes onset after 
age 30 years and prevalence of type 1 diabetes of 5% the positive predictive value of a personal 
history of autoimmune disease for type 1 diabetes will be 8.5%, with the positive predictive value for 
established ketoacidosis 16%. The predictive value of family history of autoimmunity or ketosis 
(without acidosis) is likely to be far lower. This issue is likely to contribute to the high rates of 
reported misclassification in older adults. 
A clinical feature which is strongly predictive for type 1 diabetes in older adults at diagnosis is rapid 
insulin requirement (within 3 years of diagnosis) in those who were initially treated as type 2 
diabetes (4, 6).This is particularly important as around 40% of those aged over 30 years who have 
type 1 diabetes and develop absolute insulin deficiency will be initially treated as type 2 diabetes by 
their clinician (4). Despite rapid progression to insulin half of those with missed type 1 diabetes will 
still be thought to have type 2 diabetes when assessed decades later, and are therefore ineligible for 
the education and technology needed to effectively manage their glycaemia. All those who progress 
to insulin within 3 years of diagnosis of diabetes should therefore be further investigated with 
biomarker testing (C-peptide and islet autoantibodies) to detect missed late-onset type 1 diabetes. 
We think it is vital to consider to consider diabetes duration when referring to potential 
discriminative biomarker tests that can be used to help define diabetes type.  At diagnosis where 
there is diagnostic uncertainty islet autoantibodies antibodies are most appropriate (8). In 
longstanding diabetes C-peptide is the most appropriate test and can define the need for type 1 
clinical care with a non-fasting random value of less than 200pmol/L(9).  Autoantibodies are less 
prevalent with time from diagnosis and there is limited evidence for utility of C peptide testing at 
diagnosis over and above freely available features (8, 9).  
Finally we suggest that GADA, IA2A and/or ZnT8A are the islet autoantibodies of choice in adult 
onset disease as they are robust, inexpensive, and common in adult onset disease (10). In contrast 
commercially available ICA has persistently very poor historical performance (with only a single UK 
centre still taking part in the islet autoantibody standardisation program for this assay), and insulin 
autoantibodies are infrequent in adult onset diabetes, have poor reproducibility between 
laboratories and are susceptible to false positive results where insulin has been commenced (8, 11). 
A major issue for older adult onset type 1 diabetes is getting the correct diagnosis.  This is a difficult 
diagnosis to make and has been little researched making it hard to make evidence based 
recommendations.  We hope that this area receives more attention in future research allowing 
future guidelines to give this area more emphasis. 
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